Amy DuRoss

Amy joined Frazier Healthcare Partners in August 2022 as a Senior Advisor, and brings over 25 years of entrepreneurial, corporate development, and patient advocacy experience in precision and personalized medicine. Amy is currently President, Cell and Gene Therapies (CGT) at CSafe, a Frazier portfolio company.

Prior to joining Frazier and CSafe, Amy was the Co-Founder and CEO of Vineti, a pioneering enterprise software platform digitizing the unique chain of identity and chain of custody requirements for CGT products. Vineti was incubated in partnership with the Mayo Clinic at GE Ventures, where Amy served as a Managing Director focused on equity investing and new business creation. Amy collaborated extensively with GE’s healthcare businesses and external investors and partners to establish new companies focused on solving key innovation gaps in precision and personalized medicine.

Before GE Ventures, Amy served as the Chief Business Officer at Navigenics, a personalized genomics company sold to Life Technologies (now ThermoFisher). Prior to Navigenics, she was the Co-Founder, Co-Author, and Executive Director of California’s $3 billion stem cell research ballot initiative, which led to the launch of the California Institute for Regenerative Medicine (CIRM).

Amy earned her bachelor's and two master's degrees, including her MBA, from Stanford University. She serves on the boards of Biolife Solutions (BLFS), MJH Life Sciences, Americans for Cures, and the ARM Foundation and is a lifetime member of the Aspen Institute Global Network.